Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2019
Here are the related meetings in 2020:
Cerebral Fluid Flow and Function: Lymphatics, Glymphatics and the Choroid Plexus (Q4)
Brain Therapeutics: Disruptive Technologies and Opportunities (Q3)
Neuro-Immune Interactions in the Central Nervous System (Z5)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Neural Environment in Disease: Glial Responses and Neuroinflammation (Z1)
Organizer(s) Richard Daneman, Dorothy Schafer, Michael V. Sofroniew and Vanda A. Lennon
June 16—20, 2019
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Feb 13, 2019
Abstract Deadline: Mar 13, 2019
Scholarship Deadline: Feb 13, 2019
Discounted Registration Deadline: Apr 16, 2019
Sponsored by BioLegend, Inc.
Summary of Meeting:
The response of the central nervous system to injury and disease is a complex physiological process that involves the coordinated actions of many different cell types. The interplay of neural cells and vascular cells along with the innate and adaptive immune systems determines the response to different injury and disease stimuli and whether the central nervous system will repair or degenerate. Understanding this complex cellular environment is essential to understanding disease pathogenesis, elucidating underlying disease etiology, and developing treatments for neurological and psychiatric diseases. The goal of this conference will be to bring together people who study different aspects of neurological diseases and facilitate the interchange of ideas necessary for identifying new mechanisms underlying complex intercellular interactions in the diseased nervous system. This will include people who study resident neural cells (neurons, astrocytes, oligodendrocytes), vascular cells (blood-brain barrier, lymphatics, glymphatics) and immune cells (microglia, innate peripheral immune cells, adaptive immune cells) in the context of a variety of neurodegenerative, neuroinflammatory, and neuropsychiatric diseases. Further, we will also attract people who implement different techniques including genetic mouse models, human iPSCs, invertebrate models, imaging, cell biology, and behavior in their research which will further facilitate exchange of ideas and foster collaboration. With the combined expertise at this conference, we will accelerate our ability to understand the complex neural response to injury and disease, which is a necessary step towards developing novel therapeutics for complex neurological diseases.
View Scholarships/Awards
The response of the central nervous system to injury and disease is a complex physiological process that involves the coordinated actions of many different cell types. The interplay of neural cells and vascular cells along with the innate and adaptive immune systems determines the response to different injury and disease stimuli and whether the central nervous system will repair or degenerate. Understanding this complex cellular environment is essential to understanding disease pathogenesis, elucidating underlying disease etiology, and developing treatments for neurological and psychiatric diseases. The goal of this conference will be to bring together people who study different aspects of neurological diseases and facilitate the interchange of ideas necessary for identifying new mechanisms underlying complex intercellular interactions in the diseased nervous system. This will include people who study resident neural cells (neurons, astrocytes, oligodendrocytes), vascular cells (blood-brain barrier, lymphatics, glymphatics) and immune cells (microglia, innate peripheral immune cells, adaptive immune cells) in the context of a variety of neurodegenerative, neuroinflammatory, and neuropsychiatric diseases. Further, we will also attract people who implement different techniques including genetic mouse models, human iPSCs, invertebrate models, imaging, cell biology, and behavior in their research which will further facilitate exchange of ideas and foster collaboration. With the combined expertise at this conference, we will accelerate our ability to understand the complex neural response to injury and disease, which is a necessary step towards developing novel therapeutics for complex neurological diseases.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Sunday, June 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, June 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, June 21 in order to fully experience the meeting.
SUNDAY, JUNE 16
MONDAY, JUNE 17
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
TUESDAY, JUNE 18
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
WEDNESDAY, JUNE 19
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
THURSDAY, JUNE 20
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
FRIDAY, JUNE 21
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, June 16 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, June 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, June 21 in order to fully experience the meeting.
SUNDAY, JUNE 16
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:30—09:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Richard Daneman,
University of California, San Diego, USA
*
Dorothy Schafer,
University of Massachusetts Medical School, USA
Li-Huei Tsai,
Massachusetts Institute of Technology, USA
Neuron-Glia Interaction in Health and Disease
Neuron-Glia Interaction in Health and Disease
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
08:30—09:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Fred H. Gage,
The Salk Institute for Biological Studies, USA
Marc Tessier-Lavigne,
Stanford University, USA
Molecular Control of Axon Degeneration in Development, Disease and Adult Plasticity
Molecular Control of Axon Degeneration in Development, Disease and Adult Plasticity
09:30—12:00
Neuronal Response to Injury
Meeting has ended...abstracts no longer viewable online.
*
David M. Holtzman,
Washington University, USA
TREM2 Function Regulates Aβ linked Tau Seeding and Spreading in Neuritic Plaques
TREM2 Function Regulates Aβ linked Tau Seeding and Spreading in Neuritic Plaques
Coffee Break
Eric J. Huang,
University of California, San Francisco, USA
Neuron-Glia Interaction in Human Germinal Matrix: Implications in Neurodevelopmental Disorders
Neuron-Glia Interaction in Human Germinal Matrix: Implications in Neurodevelopmental Disorders
Katie Ennis,
Biogen, USA
Short Talk: The Cytokine Receptor Fn14 is Required for Hippocampal Synaptic Plasticity Deficits that Occur Following Acute Ischemic Stroke
Short Talk: The Cytokine Receptor Fn14 is Required for Hippocampal Synaptic Plasticity Deficits that Occur Following Acute Ischemic Stroke
Lucas Cheadle,
Harvard Medical School, USA
Short Talk: Sensory Experience Engages Microglia-to-Neuron Cytokine Signaling to Remodel Developing Synapses
Short Talk: Sensory Experience Engages Microglia-to-Neuron Cytokine Signaling to Remodel Developing Synapses
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
09:30—11:45
Aggregation Mediated Toxicity
Meeting has ended...abstracts no longer viewable online.
*
Xiaobo Mao,
Johns Hopkins University, USA
Rudolph E. Tanzi,
Massachusetts General Hospital, USA
Amyloid Beta Organoid Model
Amyloid Beta Organoid Model
Coffee Break
Thomas Brannstrom,
Umea University Hospital, Sweden
Short Talk: Transmissibility of SOD1 Prion Strains Between Mice Expressing Different Mutant Human SOD1s
Short Talk: Transmissibility of SOD1 Prion Strains Between Mice Expressing Different Mutant Human SOD1s
14:30—16:30
Workshop 1: Modulating Microglia Inflammatory Signaling
*
Kim N. Green,
University of California, Irvine, USA
*
Iben Lundgaard,
University of Lund, Sweden
Ying Cao,
Peking University, China
Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition
Transcriptional Mechanism of IRF8 and PU.1 Governs Microglial Activation in Neurodegenerative Condition
Rouven Schulz,
Institute of Science and Technology Austria, Austria
Topological Classification of Microglia
Topological Classification of Microglia
Yajing Xu,
University College London, UK
Microglia Mediate Restructuring of Spinal Somatosensory Circuits During Normal Postnatal Development and After Injury
Microglia Mediate Restructuring of Spinal Somatosensory Circuits During Normal Postnatal Development and After Injury
Youtong Huang,
University of California, San Diego / Salk Institute, USA
Investigating Microglial TAM Receptors as Modulators of Alzheimer’s Pathology
Investigating Microglial TAM Receptors as Modulators of Alzheimer’s Pathology
Guy C. Brown,
University of Cambridge, UK
Blocking the Microglial P2Y6 Receptor Prevents Microglial Phagocytosis of Neurons and Synapses, and Prevents Neurodegeneration Induced by Neuroinflammation, Beta Amyloid, TAU and Ageing in vivo
Blocking the Microglial P2Y6 Receptor Prevents Microglial Phagocytosis of Neurons and Synapses, and Prevents Neurodegeneration Induced by Neuroinflammation, Beta Amyloid, TAU and Ageing in vivo
Monique S. Mendes,
University of Rochester, USA
In vivo Imaging of Microglial Self-Renewal and Maturation in the Adult Mouse Brain
In vivo Imaging of Microglial Self-Renewal and Maturation in the Adult Mouse Brain
Sanda Mimouna,
Hospital for Special Surgery, USA
The Role of Transcriptional Coregulator GRIP1 in Myeloid Cells in Neuroinflammation
The Role of Transcriptional Coregulator GRIP1 in Myeloid Cells in Neuroinflammation
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
15:00—16:30
Workshop 1
*
David V. Hansen,
Genentech, Inc., USA
Michael Henderson,
University of Pennsylvania, USA
Using Quantitative Pathology Mapping and Network Modeling to Understand α-Synuclein Spread
Using Quantitative Pathology Mapping and Network Modeling to Understand α-Synuclein Spread
Sang Su Kwak,
Genetics and Aging Research Unit, Massachusetts General Hospital, USA
Amyloid-β 42/40 Ratio Drives Tau Pathology in 3D Human Neural Cell Culture Models of Alzheimer's Disease
Amyloid-β 42/40 Ratio Drives Tau Pathology in 3D Human Neural Cell Culture Models of Alzheimer's Disease
Evan T. Lester,
University of Colorado, USA
Interactions between RNA and Tau in Models of Frontotemporal Dementia
Interactions between RNA and Tau in Models of Frontotemporal Dementia
Sílvia Porta,
Center for Neurodegenerative Disease Research, USA
Patient-Derived Frontotemporal Lobar Degeneration Brain Extracts Induce Formation and Spreading of TDP-43 Pathology in vivo
Patient-Derived Frontotemporal Lobar Degeneration Brain Extracts Induce Formation and Spreading of TDP-43 Pathology in vivo
Stephanie K. See,
University of California, San Francisco, USA
Identification of Cellular Mechanisms that Control α-Synuclein Aggregation Using a CRISPRi/a Functional Genomics Platform
Identification of Cellular Mechanisms that Control α-Synuclein Aggregation Using a CRISPRi/a Functional Genomics Platform
Meghan Kerrisk Campbell,
Alkahest, USA
A Therapeutic Human Plasma Fraction Enhances Cognitive Function in Aging and Neurodegenerative Disease through Multiple Mechanisms of Action
A Therapeutic Human Plasma Fraction Enhances Cognitive Function in Aging and Neurodegenerative Disease through Multiple Mechanisms of Action
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
17:00—19:00
Transmission and Spread of Disease Pathology
Meeting has ended...abstracts no longer viewable online.
*
Karen Hsiao Ashe,
University of Minnesota, USA
Xiaobo Mao,
Johns Hopkins University, USA
The Mechanism of Pathological alpha-synuclein Transmission
The Mechanism of Pathological alpha-synuclein Transmission
John Collinge,
University College London, UK
Prion Neurodegeneration: Towards an Effective Treatment and its Relevance for Alzheimer’s Disease
Prion Neurodegeneration: Towards an Effective Treatment and its Relevance for Alzheimer’s Disease
Karina Fog,
H. Lundbeck A/S, Denmark
Alpha-Synuclein Antibodies as Therapeutics in Synucleinopathies – How Antibodies Affect Cellular Handling of Misfolded alpha-synuclein
Alpha-Synuclein Antibodies as Therapeutics in Synucleinopathies – How Antibodies Affect Cellular Handling of Misfolded alpha-synuclein
Amanda Engstrom,
Emory University, USA
Short Talk: Pathological Tau Induces Neurodegeneration Through the Sequestration and Inhibition of LSD1 Function
Short Talk: Pathological Tau Induces Neurodegeneration Through the Sequestration and Inhibition of LSD1 Function
Xuyuan Kuang,
Rutgers University, USA
Short Talk: Association of Transmissive PolyQ Aggregates with Lipid Vesicles and Its Implications in Mutant Huntingtin Seeding
Short Talk: Association of Transmissive PolyQ Aggregates with Lipid Vesicles and Its Implications in Mutant Huntingtin Seeding
17:00—19:00
Astrocytes
Meeting has ended...abstracts no longer viewable online.
Michael V. Sofroniew,
University of California, Los Angeles, USA
Astrocyte Roles in Repair and Regeneration
Astrocyte Roles in Repair and Regeneration
Blanca Diaz Castro,
University of Edinburgh, UK
Striatal Astrocytes: Identity, Form, Function and Roles in Huntington’s Disease
Striatal Astrocytes: Identity, Form, Function and Roles in Huntington’s Disease
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Microglia and Innate Immunity
Meeting has ended...abstracts no longer viewable online.
Dorothy Schafer,
University of Massachusetts Medical School, USA
Targeting Microglia-Mediated Synapse Loss for Therapeutic Intervention in Multiple Sclerosis
Targeting Microglia-Mediated Synapse Loss for Therapeutic Intervention in Multiple Sclerosis
Kim N. Green,
University of California, Irvine, USA
Microglia Facilitate Plaque Development and Mediate the Downregulation of Synaptic Genes in Alzheimer’s Disease Mice
Microglia Facilitate Plaque Development and Mediate the Downregulation of Synaptic Genes in Alzheimer’s Disease Mice
Coffee Break
*
Anne Schaefer,
Mount Sinai School of Medicine, USA
Epigenetic and Signaling Controlled Brain Region-Specific Microglia Functions
Epigenetic and Signaling Controlled Brain Region-Specific Microglia Functions
*
Francisco J. Quintana,
Harvard Medical School, USA
Molecular Control of Astrocyte Pathogenic Activities in MS
Molecular Control of Astrocyte Pathogenic Activities in MS
Serena Becchi,
University of New South Wales, Australia
Short Talk: The Role of Microglia when Decision Making is Impaired by a High Fat and Sugar Diet in Rats
Short Talk: The Role of Microglia when Decision Making is Impaired by a High Fat and Sugar Diet in Rats
Manana Kutsia,
Okinawa Institute of Science and Technology Graduate University, Japan
Short Talk: Importance of Microglia for Neural Tissue Regeneration in Zebrafish Model of Traumatic Brain Injury
Short Talk: Importance of Microglia for Neural Tissue Regeneration in Zebrafish Model of Traumatic Brain Injury
Sandra Siegert,
Institute of Science and Technology Austria, Austria
Short Talk: Sex Specific Microglia Response to Transient Reduction of Neuronal Activity
Short Talk: Sex Specific Microglia Response to Transient Reduction of Neuronal Activity
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
08:30—11:45
New Therapeutic Opportunities
Meeting has ended...abstracts no longer viewable online.
*
Joseph W. Lewcock,
Denali Therapeutics, USA
Frank Rigo,
Ionis Pharmaceuticals, USA
RNA Targeting Therapeutics for the Treatment of Neurodegenerative Diseases
RNA Targeting Therapeutics for the Treatment of Neurodegenerative Diseases
Eric J. Huang,
University of California, San Francisco, USA
Microglia Toxicity and TDP-43 Proteinopathy in Neurodegeneration
Microglia Toxicity and TDP-43 Proteinopathy in Neurodegeneration
Coffee Break
Don W. Cleveland,
University of California, San Diego, USA
Gene Silencing Therapy for Neurodegenerative Disease
Gene Silencing Therapy for Neurodegenerative Disease
Li Gan,
Weill Cornell Medicine, USA
Sex-Dimorphic Effects of Microglial Dysfunction in Neurodegeneration
Sex-Dimorphic Effects of Microglial Dysfunction in Neurodegeneration
Dieter Willbold,
Forschungszentrum Jülich, Germany
Short Talk: First Clinical Data of the First Anti-Prionic PRI-002 that is Orally Available, Reverts Cognition Deficits, and Decelerates Neurodegeneration in Transgenic AD Mouse Models
Short Talk: First Clinical Data of the First Anti-Prionic PRI-002 that is Orally Available, Reverts Cognition Deficits, and Decelerates Neurodegeneration in Transgenic AD Mouse Models
Daniel Heinzer,
University of Zurich, Switzerland
Short Talk: Whole Genome RNAi Screen Identifies Novel Regulators of PrPC as Potential Therapeutic Targets in Prion Diseases
Short Talk: Whole Genome RNAi Screen Identifies Novel Regulators of PrPC as Potential Therapeutic Targets in Prion Diseases
Alessandro Sette,
La Jolla Institute for Allergy & Immunology, USA
Short Talk: T Cell Reactivity to Tau and Alpha-Synuclein in PD
Short Talk: T Cell Reactivity to Tau and Alpha-Synuclein in PD
17:00—19:00
Blood Brain Barrier
Meeting has ended...abstracts no longer viewable online.
Richard Daneman,
University of California, San Diego, USA
Regulation of the Blood-Brain Barrier in Health and Disease
Regulation of the Blood-Brain Barrier in Health and Disease
*
Alexandre Prat,
Université de Montréal, Canada
Influence of Cytokines on the Blood-Brain Barrier
Influence of Cytokines on the Blood-Brain Barrier
*
Eric V. Shusta,
University of Wisconsin-Madison, USA
Modeling the Neurovascular Unit Using Human iPSCs
Modeling the Neurovascular Unit Using Human iPSCs
Sidar Aydin,
University of Bern, Switzerland
Short Talk: Endothelial Antigen-Presentation Stops the Migration of CD8+ T Cells Across the Blood-Brain Barrier in Neuroinflammation
Short Talk: Endothelial Antigen-Presentation Stops the Migration of CD8+ T Cells Across the Blood-Brain Barrier in Neuroinflammation
Matthew N. McCarroll,
University of California, San Francisco, USA
Short Talk: An Inducible Zebrafish Model of Pineal Gland Ablation Reveals Dynamics of Neuronal Cell Death, Regeneration and Microgliosis in vivo
Short Talk: An Inducible Zebrafish Model of Pineal Gland Ablation Reveals Dynamics of Neuronal Cell Death, Regeneration and Microgliosis in vivo
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
17:00—19:00
Developing Effective Preclinical Disease Models
Meeting has ended...abstracts no longer viewable online.
*
Valina L. Dawson,
Johns Hopkins University School of Medicine, USA
Martin Kampmann,
University of California, San Francisco, USA
Elucidating Cellular Mechanisms and Therapeutic Strategies for Neurodegenerative Diseases with Multimodal CRISPR-based Genetic Screens in iPSC-Derived Neurons and Glia
Elucidating Cellular Mechanisms and Therapeutic Strategies for Neurodegenerative Diseases with Multimodal CRISPR-based Genetic Screens in iPSC-Derived Neurons and Glia
Fred H. Gage,
The Salk Institute for Biological Studies, USA
iPSC to Study Repair and Neurodegeneration
iPSC to Study Repair and Neurodegeneration
Zhuohao He,
University of Pennsylvania, USA
Short Talk: Studying Tau Transmission in AD and FTLD Using Novel Mouse Models
Short Talk: Studying Tau Transmission in AD and FTLD Using Novel Mouse Models
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:45
Glymphatics and Lymphatics
Meeting has ended...abstracts no longer viewable online.
*
Kari K. Alitalo,
University of Helsinki, Finland
CNS Lymphatics
CNS Lymphatics
Coffee Break
Maria Lehtinen,
Harvard Medical School, USA
Orchestration of Embryonic Brain Development by the Choroid Plexus
Orchestration of Embryonic Brain Development by the Choroid Plexus
*
Julie Siegenthaler,
University of Colorado Denver, USA
Meningeal Fibroblast Identity and Function: New Insights from scRNA-Sequencing
Meningeal Fibroblast Identity and Function: New Insights from scRNA-Sequencing
Percy Griffin,
Washington University in St. Louis, USA
Short Talk: Circadian Regulation of Neuroinflammation and Neurodegeneration by Rev-Erba
Short Talk: Circadian Regulation of Neuroinflammation and Neurodegeneration by Rev-Erba
Celia McKee,
Washington University in St. Louis, USA
Short Talk: The Astrocyte Circadian Clock Regulates Amyloid Beta Deposition and Degradation
Short Talk: The Astrocyte Circadian Clock Regulates Amyloid Beta Deposition and Degradation
Caio Mazucanti,
NIA, National Institutes of Health, USA
Short Talk: Serotonergic Regulation of Insulin Expression & Release in Choroid Plexus
Short Talk: Serotonergic Regulation of Insulin Expression & Release in Choroid Plexus
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
08:30—11:30
Translating Therapeutics for Neurodegeneration to the Clinic
Meeting has ended...abstracts no longer viewable online.
*
Karina Fog,
H. Lundbeck A/S, Denmark
Joseph W. Lewcock,
Denali Therapeutics, USA
Therapeutic Strategies Based on Human Genetics
Therapeutic Strategies Based on Human Genetics
Matthew Kennedy,
Merck Research Labs, USA
Discovery and Development of LRRK2 Inhibitors
Discovery and Development of LRRK2 Inhibitors
Coffee Break
David V. Hansen,
Genentech, Inc., USA
Microglial Activation States in Alzheimer's Disease: Are You a (Wo)man or a Mouse?
Microglial Activation States in Alzheimer's Disease: Are You a (Wo)man or a Mouse?
Jeffrey L. Cleland,
Orpheris, Inc., USA
Short Talk: OP-101: Human Safety and Pharmacokinetics of a Microglia-targeted Systemic Therapy for Neuroinflammation
Short Talk: OP-101: Human Safety and Pharmacokinetics of a Microglia-targeted Systemic Therapy for Neuroinflammation
Anna Ettorre,
4D Pharma Research Ltd, Scotland
Short Talk: From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson's Disease
Short Talk: From Screening to Pre-Clinical Efficacy of Microbiome-Derived Bacterial Strains that Modulate Neuroinflammatory and Neurodegenerative Processes in Parkinson's Disease
Garrett S. Gibbons,
University of Pennsylvania, USA
Short Talk: Conformation-Selective Tau Monoclonal Antibodies as Immunotherapy Candidates for Alzheimer's Disease (AD) and Frontotemporal Lobar Degeneration-tau (FTLD-tau)
Short Talk: Conformation-Selective Tau Monoclonal Antibodies as Immunotherapy Candidates for Alzheimer's Disease (AD) and Frontotemporal Lobar Degeneration-tau (FTLD-tau)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
14:30—16:30
Round Table Discussion from Industry, Government and Academia – Challenges and Opportunities
*
Joseph W. Lewcock,
Denali Therapeutics, USA
Gene W. Yeo,
University of California, San Diego, USA
Matthew Kennedy,
Merck Research Labs, USA
Frank Rigo,
Ionis Pharmaceuticals, USA
Amir Tamiz,
National Institute of Neurological Disorders and Stroke, USA
Aaron D. Gitler,
Stanford University School of Medicine, USA
17:00—19:00
Adaptive Immune Responses
Meeting has ended...abstracts no longer viewable online.
Vanda A. Lennon,
Mayo Clinic, USA
Astrocytic and Oligodendroglial Autoimmunity
Astrocytic and Oligodendroglial Autoimmunity
*
Daniel S. Reich,
NINDS, National Institutes of Health, USA
Imaging Lesion Repair in Multiple Sclerosis
Imaging Lesion Repair in Multiple Sclerosis
*
Jorge I. Alvarez,
University of Pennsylvania, USA
CNS Intrinsic Mechanisms Suppressing T Cell Driven Neuroinflammation
CNS Intrinsic Mechanisms Suppressing T Cell Driven Neuroinflammation
Keita Saeki,
National Institutes of Health, USA
Short Talk: IRF8 Shapes Long-Term Endotoxin Memory in Microglia
Short Talk: IRF8 Shapes Long-Term Endotoxin Memory in Microglia
Tiffany J. Petrisko,
West Virginia University, USA
Short Talk: CXCL10-CXCR3 Axis Mediates Induction of Cerebral Hyperexcitability by Peripheral Viral Challenge
Short Talk: CXCL10-CXCR3 Axis Mediates Induction of Cerebral Hyperexcitability by Peripheral Viral Challenge
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
17:00—19:00
Molecular Mechanisms of ALS/FTD
Meeting has ended...abstracts no longer viewable online.
*
Shanthini Sockanathan,
Johns Hopkins University School of Medicine, USA
Aaron D. Gitler,
Stanford University School of Medicine, USA
Expanding Mechanisms and Therapeutic Targets for Neurodegenerative Disease
Expanding Mechanisms and Therapeutic Targets for Neurodegenerative Disease
Clotilde Lagier-Tourenne,
Massachusetts General Hospital, USA
Molecular Mechanisms of Disease in ALS and FTD
Molecular Mechanisms of Disease in ALS and FTD
Gene W. Yeo,
University of California, San Diego, USA
Protein-RNA and Stress Granules Dysregulation in ALS
Protein-RNA and Stress Granules Dysregulation in ALS
Hideyuki Takahashi,
Yale University, USA
Short Talk: Progranulin Deficiency Induces Expression of Microglial TYROBP Gene Network and Differentially affects Alzheimer's disease pathologies
Short Talk: Progranulin Deficiency Induces Expression of Microglial TYROBP Gene Network and Differentially affects Alzheimer's disease pathologies
Evangelos Kiskinis,
Northwestern University Feinberg School of Medicine, USA
Short Talk: Nucleocytoplasmic Proteomic Analysis Highlights ETF1 and Nonsense Mediated Decay as Therapeutic Targets in C9ORF72-Related ALS/FTD
Short Talk: Nucleocytoplasmic Proteomic Analysis Highlights ETF1 and Nonsense Mediated Decay as Therapeutic Targets in C9ORF72-Related ALS/FTD
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:30—11:30
Oligodendrocytes and Inflammation
Meeting has ended...abstracts no longer viewable online.
David H. Rowitch,
University of Cambridge, UK
Neuronal Vulnerability and Multilineage Diversity in Multiple Sclerosis
Neuronal Vulnerability and Multilineage Diversity in Multiple Sclerosis
*
Kelly Monk,
Oregon Health & Science University, USA
Molecular and Genetic Mechanisms of Myelin Formation and Repair
Molecular and Genetic Mechanisms of Myelin Formation and Repair
Coffee Break
Dimitry Ofengeim,
Sanofi, USA
Understanding the Nature of Microglial Phenotypes through the Interplay of Cell Death and Inflammation
Understanding the Nature of Microglial Phenotypes through the Interplay of Cell Death and Inflammation
Stefan Berghoff,
Max-Planck Institut for Experimental Medicine, Germany
Short Talk: Cell-Type Specific Cholesterol Synthesis Coordinates Inflammation and Remyelination in Demyelinated Lesions
Short Talk: Cell-Type Specific Cholesterol Synthesis Coordinates Inflammation and Remyelination in Demyelinated Lesions
Claudia Fuchs,
University of Bologna, Italy
Short Talk: Loss of CDKL5 Enhances Microglia Activation: Are Neuro-Inflammatory Mechanisms Implicated in the Pathophysiology of CDKL5 Deficiency Disorder?
Short Talk: Loss of CDKL5 Enhances Microglia Activation: Are Neuro-Inflammatory Mechanisms Implicated in the Pathophysiology of CDKL5 Deficiency Disorder?
TrangKimberly T. Nguyen,
Emory University, USA
Short Talk: Proteomic Analyses Reveal that Glia-Specific and Seizure-Protective Receptors GPR37L1 and GPR37 Regulate S100A Calcium-Binding Protein Expression and Secretion
Short Talk: Proteomic Analyses Reveal that Glia-Specific and Seizure-Protective Receptors GPR37L1 and GPR37 Regulate S100A Calcium-Binding Protein Expression and Secretion
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
08:30—11:30
Drivers of Synaptic Loss in Disease
Meeting has ended...abstracts no longer viewable online.
*
Clotilde Lagier-Tourenne,
Massachusetts General Hospital, USA
Paul F. Worley,
Johns Hopkins School of Medicine, USA
Immediate Early Genes and Alzheimer’s Disease
Immediate Early Genes and Alzheimer’s Disease
Beth Stevens,
Boston Children's Hospital, Harvard Medical School, USA
Dynamic Microglia States and Functions in Health & Disease
Dynamic Microglia States and Functions in Health & Disease
Coffee Break
Karen Hsiao Ashe,
University of Minnesota, USA
Synaptic and Cognitive Dysfunction from Non-fibrillar Tau
Synaptic and Cognitive Dysfunction from Non-fibrillar Tau
Shanthini Sockanathan,
Johns Hopkins University School of Medicine, USA
Control of ADAM10 α-Secretase Cleavage of Amyloid Precursor Protein by GDE2-RECK
Control of ADAM10 α-Secretase Cleavage of Amyloid Precursor Protein by GDE2-RECK
Ryan Douglas Hallam,
University of Guelph, Canada
Short Talk: Synuclein Fibrils Inhibit Synaptic Function in Cortical Neurons through Induction of Nitrosative Stress
Short Talk: Synuclein Fibrils Inhibit Synaptic Function in Cortical Neurons through Induction of Nitrosative Stress
Claire E. Le Pichon,
NICHD, National Institutes of Health, USA
Short Talk: Enhancing the Benefits of DLK Inhibition in a Mouse Model of ALS by Restoring an Adaptive Neuronal Response
Short Talk: Enhancing the Benefits of DLK Inhibition in a Mouse Model of ALS by Restoring an Adaptive Neuronal Response
14:30—16:30
Workshop 2: Astrocyte-Microglia Crosstalk during Inflammation
*
Blanca Diaz Castro,
University of Edinburgh, UK
Lilianne Barbar,
New York Stem Cell Foundation Research Institute, USA
Developing in vitro Models of Neurodegeneration Based on Human iPSC-Derived Astrocytes
Developing in vitro Models of Neurodegeneration Based on Human iPSC-Derived Astrocytes
Cristina Gutierrez-Vazquez,
Harvard Medical School, USA
EphrinB3 Signaling Promotes Pathogenic Activities in Astrocytes during Central Nervous System Inflammation
EphrinB3 Signaling Promotes Pathogenic Activities in Astrocytes during Central Nervous System Inflammation
Weikang Cai,
Joslin Diabetes Center, USA
Insulin Signaling-Dependent ATP Release from Astrocytes is Important for Dopamine Release and Depressive-Like Behavior
Insulin Signaling-Dependent ATP Release from Astrocytes is Important for Dopamine Release and Depressive-Like Behavior
Elena Blanco-Suarez,
The Salk Institute for Biological Studies, USA
Astrocyte-Secreted Chrdl1 Promotes Synapse Maturation and Limits Synaptic Plasticity through GluA2-AMPAR Increase
Astrocyte-Secreted Chrdl1 Promotes Synapse Maturation and Limits Synaptic Plasticity through GluA2-AMPAR Increase
Martin Riccomagno,
University of California, Riverside, USA
Novel Combinatorial Approaches to Selectively Target Reactive Astrocytes
Novel Combinatorial Approaches to Selectively Target Reactive Astrocytes
Kun Leng,
University of California, San Francisco, USA
Mapping Pathways Controlling the Reactive State of Astrocytes through CRISPRi Loss-of-Function Screening and Single-Cell RNA-Seq
Mapping Pathways Controlling the Reactive State of Astrocytes through CRISPRi Loss-of-Function Screening and Single-Cell RNA-Seq
Deepa Jonnalagadda,
Sanford Burnham Prebys Medical Discovery Institute, USA
Sphingosine 1-Phosphate Signaling Effects in Immediate-Early Astrocytes (ieAstrocytes)
Sphingosine 1-Phosphate Signaling Effects in Immediate-Early Astrocytes (ieAstrocytes)
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
15:00—16:30
Workshop 2
*
Katerina Akassoglou,
University of California, San Francisco, USA
Irina Alexandra Leaf,
Biogen, USA
Reverse Translational Multimodal Approach to Identify CSF Signatures Associated with Disease Progression in MS
Reverse Translational Multimodal Approach to Identify CSF Signatures Associated with Disease Progression in MS
Chelsey J. LeBlang,
Boston University School of Medicine, USA
Modulation of the Inflammatory Response by the RNA-binding Protein TIA1 in the P301S Mouse Model of Tauopathy
Modulation of the Inflammatory Response by the RNA-binding Protein TIA1 in the P301S Mouse Model of Tauopathy
Yihang Li,
Dana-Farber Cancer Institute, USA
SARM1 Interacts with the Bclw/IP3R Pathway in Paclitaxel-Induced Axon Degeneration
SARM1 Interacts with the Bclw/IP3R Pathway in Paclitaxel-Induced Axon Degeneration
Michael A. Lodato,
Boston Children's Hospital, USA
Single-Cell, Whole-Genome Sequencing Reveals Mechanisms of DNA Damage and Somatic Mutation in the Human Brain during Aging and in Neurodegeneration
Single-Cell, Whole-Genome Sequencing Reveals Mechanisms of DNA Damage and Somatic Mutation in the Human Brain during Aging and in Neurodegeneration
Michaela O. Lunn,
Carleton University, Canada
Contribution of Lrrk2 to the Modulation of Host Immunity during Infection
Contribution of Lrrk2 to the Modulation of Host Immunity during Infection
Jing Yang,
Peking University, China
Local Degeneration of Catecholaminergic Axons Acts as the Protective Mechanism in Colitis
Local Degeneration of Catecholaminergic Axons Acts as the Protective Mechanism in Colitis
Samara Reck-Peterson,
University of California, San Diego, USA
A Structural and Mechanistic Model for the Regulation of LRRK2’s Interaction with Microtubules
A Structural and Mechanistic Model for the Regulation of LRRK2’s Interaction with Microtubules
17:00—18:45
Hot Topics
Meeting has ended...abstracts no longer viewable online.
Erik M. Ullian,
University of California, San Francisco, USA
Novel Three-Dimensional Astrocyte-Containing Organoids Recapitulate Key Aspects of Human Neurodegenerative Disease
Novel Three-Dimensional Astrocyte-Containing Organoids Recapitulate Key Aspects of Human Neurodegenerative Disease
*
Long-Jun Wu,
Mayo Clinic, USA
Neuronal Network Activity Controls Microglial Process Surveillance in Awake Mice via Norepinephrine Signaling
Neuronal Network Activity Controls Microglial Process Surveillance in Awake Mice via Norepinephrine Signaling
*
Yi Ren,
Florida State University, USA
The Inflammatory Mechanisms Involved in Myelin-Debris-Induced Pathological Changes in Neural Injury
The Inflammatory Mechanisms Involved in Myelin-Debris-Induced Pathological Changes in Neural Injury
Julia A. Kuhn,
Genentech, Inc., USA
Short Talk: Sex Differences in Microglial Contributions to Pain
Short Talk: Sex Differences in Microglial Contributions to Pain
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
17:00—18:45
Glial Contributors to Neurodegeneration
Meeting has ended...abstracts no longer viewable online.
*
Beth Stevens,
Boston Children's Hospital, Harvard Medical School, USA
Mathew M. Blurton-Jones,
University of California, Irvine, USA
Development of a Chimeric Model to Study and Manipulate Human Microglia in vivo
Development of a Chimeric Model to Study and Manipulate Human Microglia in vivo
Katerina Akassoglou,
University of California, San Francisco, USA
Neurovascular Interactions: Mechanisms, Imaging, Therapeutics
Neurovascular Interactions: Mechanisms, Imaging, Therapeutics
Anastasia Efthymiou,
Icahn School of Medicine at Mount Sinai, USA
Short Talk: Investigating the Effect of the MS4A locus on Alzheimer's Disease Risk
Short Talk: Investigating the Effect of the MS4A locus on Alzheimer's Disease Risk
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Meeting has ended...abstracts no longer viewable online.
Vanda A. Lennon,
Mayo Clinic, USA
Following Session is for Neurodegenerative Diseases: New Insights and Therapeutic Opportunities (Z2)
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions
Meeting has ended...abstracts no longer viewable online.
Valina L. Dawson,
Johns Hopkins University School of Medicine, USA
Joseph W. Lewcock,
Denali Therapeutics, USA
Fred H. Gage,
The Salk Institute for Biological Studies, USA
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
|
|
We gratefully acknowledge additional support from these exhibitors at this conference:
|
|
Please stop by to meet these exhibitors during the conference.
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
|
|
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
